(2S)-2-Methylbutanoic acid (1S,3S,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3-hydroxy-7-methyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]-ethyl]-naphthalen-1-yl ester, commonly known as Pravastatin, is a potent and selective inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the rate-limiting step in cholesterol biosynthesis. Pravastatin is a prodrug, activated in vivo by hydrolysis of the ester group, and is derived from the fungal metabolite mevastatin. As a member of the statin class, Pravastatin is a widely used active pharmaceutical ingredient (API) for the treatment of hypercholesterolemia and dyslipidemia. Its primary therapeutic application is to lower elevated levels of low-density lipoprotein (LDL) cholesterol and triglycerides, thereby reducing the risk of cardiovascular events such as myocardial infarction and stroke. It is also indicated for the primary and secondary prevention of coronary heart disease. Pravastatin is distinguished by its hydrophilic nature, which contributes to its selective action on hepatic cells and a favorable side-effect profile with a lower incidence of muscle-related adverse events compared to some lipophilic statins. It is typically administered orally in its sodium salt form.